✦ LIBER ✦

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

✍ Scribed by von Pawel, Joachim; Harvey, Jimmie H.; Spigel, David R.; Dediu, Mircea; Reck, Martin; Cebotaru, Cristina L.; Humphreys, Robin C.; Gribbin, Matthew J.; Fox, Norma Lynn; Camidge, D. Ross

Book ID: 121769136
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 569 KB
Volume: 15
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2013.12.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of mapatumumab, a fully h

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

✍ Trarbach, T; Moehler, M; Heinemann, V; Köhne, C-H; Przyborek, M; Schulz, C; Snel 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 318 KB

208 HGS-ETR1, a fully human monoclonal a

208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial

✍ S.J. Hotte; A.M. Oza; L.H. Le; M. MacLean; A. Iacobucci; A. Corey; N.L. Fox; H.W 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase 2 study of mapatumumab, a fully hu

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

✍ Greco, F. Anthony; Bonomi, Philip; Crawford, Jeffrey; Kelly, Karen; Oh, Yun; Hal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 214 KB

197 A phase I and pharmacokinetic (PK) s

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

✍ J. de Bono; G. Attard; R. Plummer; S. Pacey; C. Bale; L. Vidal; A. Greystoke; N. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 138 KB